126P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with checkpoint inhibitor (CPI)-experienced advanced non-small cell lung cancer (NSCLC). (December 2022) - Frentzas, S.; Meniawy, T.; Kao, S.C-H.; Coward, J.; Clay, T.D.; Singhal, N.; Black, A.; Xu, W.; Kumar, R.; Lee, Y.; Lee, G-W.; Liao, W.; et al.